SubHero Banner
Text

Bavencio® (avelumab) – Expanded indication

June 30, 2020 - Pfizer and EMD Serono announced the FDA approval of Bavencio (avelumab), for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

Download PDF